Product Reports Resources Pricing Login Book a demo

Synchron

Biotech & Life Sciences · New York City, United States · Founded 2012

Developing implantable brain-computer interfaces to restore neurological function and enable direct communication between the brain and external devices MoreLess

Synchron is a pioneering company in the medical technology sector, aiming to revolutionize healthcare by providing unprecedented access to brain data. Founded in 2012, Synchron focuses on developing brain-computer interface (BCI) technology that allows individuals to control digital devices using their thoughts. This technology is particularly transformative for patients with severe paralysis, offering them a new level of autonomy and social connection.

The company's flagship product involves a minimally invasive endovascular procedure, akin to the placement of stents, which eliminates the need for open brain surgery. This procedure allows the BCI to be implanted safely and efficiently, making it accessible to a broader range of patients.

Synchron primarily serves patients with neurological conditions that impair their ability to communicate or move. These clients benefit from the ability to control computers and other digital devices using their thoughts, significantly improving their quality of life. The company operates in the medical technology market, which is rapidly growing due to advancements in healthcare and increasing demand for innovative treatments.

The business model of Synchron revolves around the development, clinical testing, and commercialization of its BCI technology. The company generates revenue through the sale of its medical devices and related services. Additionally, Synchron may engage in partnerships with healthcare providers and institutions to expand the reach and application of its technology.

The leadership team at Synchron comprises global experts in neuroscience, vascular bionics, and medical technology, including CEO Tom Oxley and Founding Director Nick Opie. Their combined expertise drives the company's mission to empower patients and transform medicine.

In summary, Synchron is at the forefront of medical innovation, offering groundbreaking solutions for patients with severe neurological impairments. By leveraging advanced BCI technology, the company is making significant strides in improving patient autonomy and social connectivity.

Keywords: Brain-computer interface, minimally invasive, endovascular procedure, neurological conditions, patient autonomy, digital control, medical technology, healthcare innovation, paralysis treatment, brain data.

Company overview

Synchron company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2012
Headquarters
New York City, United States
Employees
131
Open positions
37
Dealroom signal
72.8
Investment activity
1 companies · latest Feb 2024
Capital deployed
Preferred round
GROWTH EQUITY NON VC
client focusb2bsub industryBioTechnologysub industryMedical Devicesbusiness modelManufacturingsectorRehabilitationindustryHealthsectorBiotechnologysectorNeurologysectorNon-Invasive medical devices and treatmentssectorSpinoutsectorDisability techsectorSustainable Development GoalssectorBiotech and PharmasectorBrain Computer Interfaces

Valuation & funding

Synchron funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES DOther financing Nov 2025 $200M $900M Qatar Investment Authority · Bezos Expeditions · ARCH Venture Partners · Protocol Labs
SERIES COther financing Dec 2022 $75M $300M ARCH Venture Partners · Forepont Capital Partners · Alumni Ventures · Reliance Industries
LATE VCOther financing Feb 2022 $0 Max Hodak
GRANTOther financing Aug 2021 $10M National Institutes of Health
SERIES BOther financing Jun 2021 $34M $135M Forepont Capital Partners · Subversive Capital · ID8 Investments · Thomas Reardon
GRANTOther financing Jul 2020 Undisclosed
SERIES AOther financing Apr 2017 DARPA · NeuroTechnology Investors
SPINOUTOther financing Jan 2012 University of Melbourne
EARLY VCOther financing Jan 2005 Sigma Partners
Showing 9 recorded eventsUnlock the complete deal history →

Growth signals

Synchron website traffic

Latest recorded traffic for Synchron is 29K monthly website visits, up 0% over the last three months. Synchron's team declined 0.8% over the past year.

Latest monthly visits29K 3-month web change0% 1-year team growth-0.8%
Monthly website visits82 observations · Dec 2018–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Synchron compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Capital deployed

Synchron investments and acquisitions

Recent portfolio relationships for companies that also act as investors or acquirers.

Talent graph

Synchron's talent

Book a demo to see the people
Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

32 investors on Synchron's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 1 investor entered at this stage
National Institutes of Health
Series A 14 investors entered at this stage
Sigma Partners
NeuroTechnology Investors
DARPA
Khosla Ventures
Forepont Capital Partners
Subversive Capital
ID8 Investments
Thomas Reardon
General Advance
Shanda Group
Arani Bose
re.Mind Capital
METIS innovative
Wesley College
Series B+ 17 investors entered at this stage
Max Hodak
ARCH Venture Partners
Alumni Ventures
Reliance Industries
Moore Strategic Ventures
Gates Frontier
Greenoaks Capital Partners
Bezos Expeditions
University of Melbourne
Project X
Double Point Ventures
Qatar Investment Authority
Protocol Labs
K5 Global
T.Rx Capital
Australian National Reconstruction Fund
IQT Group

Global footprint

Where Synchron has talent and traffic

Workforce by country
5 countries with
team presence
🇺🇸 United States89.6%
🇦🇺 Australia6.5%
🇮🇪 Ireland1.3%
🇨🇦 Canada1.3%
🇬🇧 United Kingdom1.3%
5 countries shown

In the news

Latest news about Synchron

Recent press, funding announcements, and product moves mentioning Synchron — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Synchron

An AI-synthesized read of the highest-engagement posts about Synchron on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Synchron’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.